Kendal Square, MA– Eli Lilly plans to open a drug delivery and innovation center in Kendall Square, Massachusetts. The focus of this new innovation center will be on drug delivery device innovation (specific to diabetes), immunology, chronic pain, and neural degeneration.
“As we start to look at this, we’re looking at what kind of technology changes and evolution is going to allow for a simple, convenient delivery and part of that is the technology part and the technology that’s coming together about mobile technology and so on,” he said. “We’ll seek to work with similar leading experts there in Boston in the Cambridge area to think about, research, and explore some of those technologies and potential applications for our company.” -Senior Director of Global Corporate Communications Edward Sagebiel
Eli Lilly currently has 4 apps in Apple’s app store, one of which, Glucagon is a tool for teaching patients how to use injectable medications. The Glucagon app serves as a virtual practice tool with steps for administering Glucagon, managing the expiration of multiple kits, and receiving helpful tips.
“New drug delivery and device innovation is critically important to Lilly’s growing portfolio of potential medicines, particularly in our focus areas of diabetes, neurodegeneration, immunology and pain,”Jan Lundberg, Ph.D., executive vice president of science and technology and president of Lilly Research Laboratories said in a statement. “The best therapies of the future will marry breakthrough scientific discovery with customer-friendly devices. That’s what will make life better for people who need our medicines and give Lilly a true competitive edge.”
This initiative serves as a perfect example of the power and influence that the “innovation from insiders” trend we have been watching closely this year has had on the pharmaceutical industry.
About the Author:
As Managing Director of Innovation and Insights for Syneos Health Communications, Leigh is responsible for building and scaling a global team of healthcare experts who together help life science leaders better understand the complex lives, influences and expectations of their customers. Specifically, they uncover actionable insights that fuel empathy and creativity; lead co-creation events that let marketers learn from peers, trends, and new possibilities; and help clients identify the most valuable and useful new customer experiences to create.
Leigh has worked with Fortune 1000 companies to craft their digital, mobile, social and CRM strategies for nearly 20 years.She’s worked for category-leading agencies in retail, public affairs, B2B technology, and higher education. Prior to moving to Syneos Health Communications, she held several leadership roles at our largest agency, GSW. There, she founded an innovation practice fueled by the zeitgeist and spearheaded digital and innovation thinking across the business.
Leigh has taken a special interest in complex healthcare products that can change lives in meaningful ways. She was recently a strategic lead on the 3rd largest launch in pharmaceutical history: Tecfidera. Before that she had keys roles with Eli Lilly Oncology, Abbott Nutrition, Amgen Cardiovascular, and Eli Lilly Diabetes.
A critical part of Leigh’s work is trends and new ideas. Every year, she convenes a group of trend watchers from across our global network to identify the shifts most critical to healthcare marketers. This year, she led over 250 experts to experts to focus on the most important changes in the commercial, consumer, marketing, digital and healthcare landscapes. (See reports at trends.health)
Leigh is a sought-after writer and speaker. Recognized as one of the most inspiring people in the pharmaceutical industry by PharmaVoice and Top 10 Innovation Catalysts of 2017 by MM&M, Leigh also was recognized as a Rising Star by the Healthcare Businesswomen's Association (HBA) for her overt passion, industry thought leadership and significant contributions in new business, strategy and mentoring.
